1985
DOI: 10.1093/carcin/6.5.711
|View full text |Cite
|
Sign up to set email alerts
|

Cell cycle perturbations following DNA damage in the presence of ADP-ribosylation inhibitors

Abstract: Cell cycle analysis by DNA flow cytofluorimetry and autoradiography has been utilized to investigate the effects of 3-methoxybenzamide (MBA), a potent inhibitor of ADP-ribosylation reactions, on cell cycle progression in N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-treated C3H10T1/2 cells. Following a dose of 6.8 microM MNNG, the presence of MBA resulted in an increased length of S phase from approximately 6.5 h to 10 h and in an accumulation of cells in G2 with a mitosis delay of 12 h. Progression to the next … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
10
0

Year Published

1992
1992
2016
2016

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(12 citation statements)
references
References 0 publications
2
10
0
Order By: Relevance
“…PARP-1 is a nuclear enzyme that uses NAD+ as a substrate to catalyze the covalent attachment of ADP-ribose units on nuclear acceptor proteins or on PARP-1 itself 30 . In response to stress signals, PARP-1 is activated and plays key roles in DNA repair 31–33 , apoptosis 34, 35 , chromatin modulation and transcription 36, 37 and cell cycle regulation 3841 . Many reports demonstrate that PARP-1 inhibition by genetic deletion or chemical inhibitors decreases angiogenesis during melanoma tumor growth, a transplanted lung cancer model or other pathological conditions 4245 .…”
Section: Resultsmentioning
confidence: 99%
“…PARP-1 is a nuclear enzyme that uses NAD+ as a substrate to catalyze the covalent attachment of ADP-ribose units on nuclear acceptor proteins or on PARP-1 itself 30 . In response to stress signals, PARP-1 is activated and plays key roles in DNA repair 31–33 , apoptosis 34, 35 , chromatin modulation and transcription 36, 37 and cell cycle regulation 3841 . Many reports demonstrate that PARP-1 inhibition by genetic deletion or chemical inhibitors decreases angiogenesis during melanoma tumor growth, a transplanted lung cancer model or other pathological conditions 4245 .…”
Section: Resultsmentioning
confidence: 99%
“…In contrast, the three PARP-DBD-expressing cell lines exhibited an -2-fold increase in the fraction of cells in G2 + M after MNNG treatment. The p53-mediated G1 arrest is absent in HeLa cells (23); however, previous studies have shown that p53-positive cell lines simultaneously exposed to 3-aminobenzamide, a potent PARP inhibitor, and to alkylating agents exhibit an accumulation in G2 + M phase but not in G1 (24,25). Taken together, these results indicate that after exposure to low levels of alkylating agents, inhibition of PARP, either by 3-aminobenzamide or by production of its DBD, results in a delay in G2 + M, independent of p53 function, strongly suggesting that PARP is critical for passing through the G2 checkpoint.…”
Section: Resultsmentioning
confidence: 99%
“…Furthermore, multiple reports show that PARP inhibitors increase the cytotoxicity of DNA-damaging agents and IR (19 -21). This is manifested by a delay in the progression through the S phase and accumulation of cells in G 2 /M (22,23). Although viable, both PARP-1 and PARP-2 knock-out mice display an acute sensitivity to IR and alkylating agents (24,25).…”
mentioning
confidence: 99%